Skip to main content
Clinical Trials/NCT00370149
NCT00370149
Terminated
Phase 4

A Randomized, Controlled Trial of Catheter Related Infectious Event Rates Using Antibiotic-impregnated Catheters vs. Conventional Catheters in Pediatric Cardiovascular Surgery Patients

Indiana University School of Medicine1 site in 1 country326 target enrollmentSeptember 2006

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Infection Prevention
Sponsor
Indiana University School of Medicine
Enrollment
326
Locations
1
Primary Endpoint
Incidence of Catheter-related Bloodstream Infections (CRBSI) Per 1000 Catheter Days
Status
Terminated
Last Updated
10 years ago

Overview

Brief Summary

The primary purpose of the study is to determine if a therapeutic difference exists between central venous catheters impregnated with minocycline and rifampin and conventional catheters not impregnated with antibiotics when used in children at high risk for bloodstream infections (CABSI) after cardiac surgery.

Detailed Description

The standard central venous catheter (CVC) is now commonly used for infants, children, and adults. The antibiotic-coated CVC is a newer CVC gaining popularity for use in adults. The Food and Drug Administration (FDA) and the Center for Disease Control (CDC) support use of the antibiotic-coated CVC for adult patients. But the FDA and CDC have not yet endorsed use of the antibiotic-coated CVC for infants and children due to lack of research on this CVC in infants and children.

Registry
clinicaltrials.gov
Start Date
September 2006
End Date
May 2010
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age \< 18 years
  • Cardiovascular surgery patient with a case complexity warranting CVC placement longer than 3 days
  • Study devices of appropriate size for patient use without modification
  • Informed consent obtained prior to patient entering the operating room

Exclusion Criteria

  • Age ≥ 18 years
  • Drug allergy to minocycline, other tetracyclines, or rifampin
  • Ventricular assist device (VAD) therapy
  • Extracorporeal membrane oxygenation (ECMO) therapy
  • Patients undergoing cardiac transplant
  • Any active infection or being treated for bacteremia at the time of randomization

Outcomes

Primary Outcomes

Incidence of Catheter-related Bloodstream Infections (CRBSI) Per 1000 Catheter Days

Time Frame: Participants were followed for the duration of the hospital stay, an average of 6 days.

Rates of CRBSI defined as 1. micro-organism isolated from a blood culture; 2. Clinical manifestations of infection such as fever (≥38 C) and/or hypotension (defined according to age-related practice guidelines for systolic blood pressure); 3. No apparent source for the bloodstream infection except for the catheter.

Secondary Outcomes

  • Episodes of Clinical Sepsis and/or Infection With Identified Source Other Than Catheter(Participants were followed for the duration of hospital stay, an average of 6 days.)
  • Death(Participants were followed for the duration of the hospital stay, an average of 6 days.)

Study Sites (1)

Loading locations...

Similar Trials